Disclosed is a preparation method for triphenylchloromethane, comprising the following steps: adding hydrochloric acid or a mixture of hydrochloric acid and Lewis acid to a mixture of triphenylmethanol and an organic solvent; stirring for reaction; removing the water layer after the completion of reaction to obtain an organic solution containing triphenylchloromethane. In the method, the conversion rate of triphenylmethanol is almost quantitative to be above 99%, and the content of triphenylchloromethane in the product obtained is above 99%. The operation is simple, and no waste gas is generated. Therefore, the method is environmentally friendly and suitable for industrialized production and can achieve better economic benefits.

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R.sup.1, and R.sup.2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1. ##STR00001##

Disclosed is a preparation method for triphenylchloromethane, comprising the following steps: adding hydrochloric acid or a mixture of hydrochloric acid and Lewis acid to a mixture of triphenylmethanol and an organic solvent; stirring for reaction; removing the water layer after the completion of reaction to obtain an organic solution containing triphenylchloromethane. In the method, the conversion rate of triphenylmethanol is almost quantitative to be above 99%, and the content of triphenylchloromethane in the product obtained is above 99%. The operation is simple, and no waste gas is generated. Therefore, the method is environmentally friendly and suitable for industrialized production and can achieve better economic benefits.

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R.sup.1, and R.sup.2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

##STR00001##